Post Profile






Durvalumab improves progression-free survival in stage III lung cancer

(European Society for Medical Oncology) Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage III lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine.
read more

share

Related Posts


Osimertinib improves symptoms in advanced lung cancer patients

Diseases & Conditions / Cancer : EurekAlert: Cancer

(European Society for Medical Oncology) Osimertinib improves cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented at t...

Study shows white blood cell boosting drugs safe during chemo-radiotherapy of lung cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo-r...

Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

Health : EurekAlert: Health

(European Society for Medical Oncology) Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the fir...

Combination Immunotherapy Improves Kidney Cancer Survival

Health : Newswise Medical News

A combination immunotherapy treatment showed better overall survival in patients with previously untreated advanced or metastatic renal cell carcinoma than current therapy, according to results from a phase 3 clinical trial presente...

Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer

Health : Newswise Medical News

Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE ...

Comments


Copyright © 2016 Regator, LLC